ArticleCancer chemotherapy and pharmacology2023

A phase I trial of the pan-ERBB inhibitor neratinib combined with the MEK inhibitor trametinib in patients with advanced cancer with EGFR mutation/amplification, HER2 mutation/amplification, HER3/4 mutation or KRAS mutation.

Sarina A Piha-Paul et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.